Irritable Bowel Syndrome with Constipation Drugs Market Size, Share, Growth and Forecast To 2025: Brisk Insights

According to a recently published report by Brisk Insights, the Global Irritable Bowel Syndrome with Constipation (IBS-C) Drugs Market is expected to grow at the CAGR of 6.3% during 2017-2025. The global IBS-C drug market is segmented on the basis of type of drug, prescription and geography. The report on global IBS-C drug market (by drug, prescription and geography) provides a detailed overview and predictive analysis of the market.

Full report available on IBS-C drug Market: Global Industry Size, Growth, Share and Forecast to 2025 report at

Market Insights

The global irritable bowel syndrome with constipation IBS-C drugs market is anticipated to grow significantly during forecast period due to increase healthcare awareness and modern unhealthy dietary habits. It is observed that more than 10% of global population is affected with IBS-C; however, it is more prevalent females and in developed countries. It is observed that lubiprostone and linaclotide are most widely used in market for treatment of IBS-C due to its proven efficiency and established safety profile. There are different promising drugs in pipeline such as Plecanatide, Ibodutant, Tenapanor, Relenopride and Lovastatin anticipated to drive market growth during forecast period. Currently, Europe is expected to be the largest regional market for IBS-C drugs followed by North America because prevalence of IBS is more in developed economies, modern dietary habits, unhealthy work conditions and adoption of branded IBS-C drugs in developed economies are influencing the market growth. Significant unmet needs and increasing healthcare awareness would create significant opportunity for the market players in Asia Pacific regional market.

Scope of the report

1. Global IBS-C Market, by Drug Type, 2015–2025 ($ Million)

1.1. Lubiprostone
1.2. Linaclotide
1.3. Stimulant Laxatives
1.3.1. Bisacodyl
1.3.2. Senna
1.4. Osmotic Laxatives
1.4.1. Lactulose
1.4.2. Polyethylene Glycol
1.5. Others (Psyllium) – Qualitative Information
1.6. Pipeline Drug Analysis: Plecanatide, Ibodutant, Tenapanor, Relenopride, Lovastatin

2. Global IBS-C Market, by Prescription Type, 2015–2025 ($ Million)

2.1. Prescription Drugs
2.2. Over the Counter Drugs

3. Global IBS-C Market, by Geography, 2015-2025 ($ Million)

3.1. North America
3.1.1. U.S.
3.1.2. Canada
3.2. Europe
3.2.1. U.K.
3.2.2. Germany
3.2.3. France
3.2.4. Rest of Europe
3.3. Asia Pacific
3.3.1. Japan
3.3.2. China
3.3.3. Rest of Asia Pacific
3.4. Latin America (LATAM)
3.4.1. Brazil
3.4.2. Mexico
3.4.3. Rest of Latin America
3.5. Middle East and Africa (MEA)
3.5.1. GCC
3.5.2. Rest of Middle East and Africa

4. Company Profiles

4.1. Abbott Laboratories
4.2. Ardelyx
4.3. Astellas Pharmaceuticals
4.4. Catalent Pharmaceuticals Solutions
4.5. Nestle
4.6. Novartis
4.7. Sucampo Pharmaceuticals
4.8. Synergy Pharmaceuticals
4.9. Synthetic Biologics, Inc.
4.10. Other Major Players

About Us:

Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.

Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.

Contact Us:

Jennifer Smith

Office 1094

109 Vernon House, Friar Lane, Nottingham, NG1 6DQ

United Kingdom

Phone: +448081890034 (UK)